Phase III
Results from multiple Phase III trials show consistent improvements in pain relief and physical function.
Pfizer and Opko Health reported their Phase III clinical trial of somatrogan met the primary endpoint compared to Genotropin (somatropin) for treating children 3 to 18 years of age with growth hormone deficiency.
Bristol Myers Squibb announced today that its Phase III CheckMate -816 trial met its primary endpoint of pathologic complete response (pCR) in patients with resectable non-small cell lung cancer.
This comes after data from an interim analysis suggested that the trial was unlikely to meet its primary endpoint.
A few days ago, CNBC reported that five patients, three in Moderna’s and two in Pfizer’s Phase III trials, had experienced more severe, although transient side effects.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 6, 2020.
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
AstraZeneca’s Phase III COVID-19 vaccine study in the United States is being further delayed due to the U.S. FDA wanting to take a more thorough look at information related to the trial.
Alnilam – the bright center star in the middle of Orion’s belt – has navigated its namesake Alnylam to positive results in their ILLUMINATE-B Phase III clinical trial evaluating RNAi therapeutic, lumasiran, in young children with Primary hyperoxaluria Type 1 (PH1).
Although still preliminary, Regeneron Pharmaceuticals announced early data from its Phase I/II/III trial of its antibody cocktail, REGN-COV2, against COVID-19.
PRESS RELEASES